Acetyl-L-Carnitine/α-Lipoic Acid Supplements

OVERVIEW

This material was prepared for the National Cancer Institute (NCI) for consideration by the Chemical Selection Working Group (CSWG) by Technical Resources International, Inc. under contract no. N02-07007

Acetyl-L-carnitine/α-lipoic acid supplements were identified by the National Cancer Institute (NCI) Division of Cancer Biology (DCB) as a popular combination anti-aging and vitality formula that would be consumed over a period of many years to maximize potential beneficial effects.

In this formulation, acetyl-L-carnitine hydrochloride is thought to increase general metabolic activity and to improve cognitive function. α-Lipoic acid is added as a potent antioxidant to protect against the elevated levels of free radicals produced from the increase in metabolism. Thus, acetyl carnitine/α-lipoic acid dietary supplements have a potential market of tens of millions of middle-aged and elderly Americans who desire to improve their general health.

Acetyl-L-carnitine is a mitochondrial metabolite that facilitates the movement of fatty acids into the mitochondria for energy and is also used to generate acetyl coenzyme A. α-Lipoic acid is a coenzyme involved in mitochondrial ATP production and its reduced form can recycle other antioxidants.

Virtually no information on the potential toxicity of acetyl-L-carnitine/α-lipoic acid combinations was found in the available literature. α-Lipoic acid was not mutagenic in the Ames assay.

INPUT FROM GOVERNMENT AGENCIES/INDUSTRY

Dr. Skip Eastin, National Institute of Environmental Health Sciences, National Institutes of Health, provided information on α-lipoic acid.
NOMINATION OF ACETYL-L-CARNITINE & ALPHA-LIPOIC ACID TO THE NTP

Based on a review of available relevant literature and the recommendations of the Chemical Selection Working Group (CSWG) held on July 1, 2003, NCI nominates acetyl-L-carnitine, α-lipoic acid, and their combination used in dietary supplements for testing by the National Toxicology Program (NTP) and forwards the following information:

- The attached Summary of Data for Chemical Selection
- Copies of references cited in the Summary of Data for Chemical Selection
- CSWG recommendations to evaluate the chemicals separately and in combination in toxicity studies using mammals.

PRIORITY FOR TESTING

The CSWG recommended that testing of these chemicals be carried out with high priority.

COMMENTS

CSWG members felt that special emphasis should be given to the thyroid as an endpoint.

CSWG members suggested that the Office of Dietary Supplements, National Institutes of Health, be consulted.

Approximately one year following the presentation of acetyl-L-carnitine/α-lipoic acid at the CSWG meeting on July 1, 2003, a search of PubMed was conducted to identify new published information.

One toxicity study was identified. This study indicated that lipoic acid is 10 times more acutely toxic to cats than in humans, dogs, or rats. The maximum tolerated dose was <30 mg/kg in cats with hepatocellular toxicity reported (Hill et al., 2004).
Although no new studies of acetyl-L-carnitine/α-lipoic acid combinations were identified in the literature search, several studies describing protective effects for lipoic acid were published in the last year. As examples, these studies include:

- A report that the potency of lipoic acid to protect glutathione S-transferase P1-1 against peroxynitrite-induced damage might be of therapeutic interest (Rezk et al., 2004).
- A report that combined lipoic acid and dimercaptosuccinic acid provided therapeutic benefits to reduce renal damage from lead acetate in male Wistar rats (Sivaprasad et al., 2004).
- A report that α-lipoic acid treatment partially but significantly reversed diabetes in streptozotocin diabetic rats (Kumar & Prashanth, 2004).
- A report that lipoic acid pretreatment attenuated ferric chloride-induced seizures in male S-D rats (Meyerhoff et al., 2004).
- A report indicating that acetyl-L-carnitine had beneficial effects in animal models of Parkinson’s disease (Beal, 2004).

Citations to the above reports are included in the reference list and abstracts of the studies are included in the attached references.
SUMMARY OF DATA FOR CHEMICAL SELECTION

CHEMICAL IDENTIFICATION

Acetyl-L-Carnitine Hydrochloride

CAS Registry Numbers: 5080-50-2

Chemical Abstracts Service Name: 1-Propanaminium, 2-(acetyloxy)-3-carboxy-N,N,N-trimethyl-chloride, (R)- (9Cl)

Synonyms and Trade Name: Acetyl-L-carnitine chloride; acetylcarnitine L-form hydrochloride; o-Acetyl-L-carnitine hydrochloride; L-O-Acetylcarnitine chloride; ALC; ALCAR; Branigen; levacecarnine hydrochloride; Nicetile; Normobren; ST-200; Zibren (Budavari, 2001; ChemID, 2003; Sigma-Aldrich, 2003a)

Structural Class: Carnitine derivative

Structure, Molecular Formula, and Molecular Weight:

\[
\text{\text{CH}_9\text{H}_{17}\text{NO}_4\cdot\text{HCl}} \quad \text{Mol. wt.: 239.70}
\]

Chemical and Physical Properties:

- **Description:** White crystalline powder (Sigma-Aldrich, 2003b)
- **Melting Point:** 187 °C (Budavari, 2001)
Solubility: Soluble in water and alcohol; insoluble in ether (Budavari, 2001)

Reactivity: Stable (Budavari, 2001)

α-Lipoic Acid

CAS Registry Number: 62-46-4

Chemical Abstracts Service Name: 1,2-Dithiolane-3-pentanoic acid (9CI)

Synonyms and Trade Names: 1,2-Dithiolane-3-valeric acid; acetate-replacing factor; Biletan; 5-(1,2-dithiolan-3-y1)valeric acid; 6,8-dithiooctanoic acid; Heparlipon; lipoic acid; Liposan; Lipothion; protogen A; pyruvate oxidation factor; Thioctacid; thiotic acid; 6,8-thioctic acid; 6-thioctic acid; thioctidase; thiooctanoic acid; Tioctan (Budavari, 2001; ChemFinder, 2003; ChemID, 2003)

Structural Class: Dithiolane carboxylic acid

Structure, Molecular Formula, and Molecular Weight:

\[
\text{C}_{8}\text{H}_{14}\text{O}_{2}\text{S}_{2}
\]

Mol. wt.: 206.33

Chemical and Physical Properties:

Description: Yellow powder (Sigma-Aldrich, 2003b)

Melting Point: 60-61 °C (Lewis, 2001; Lide, 2003)

Boiling Point: 160-165 °C (Lewis, 2001)

Solubility: Insoluble in water; soluble in fat solvents (Lewis, 2001; Lide, 2003)

Reactivity: Forms a water-soluble sodium salt (Lewis, 2001)
**Technical Products and Impurities:** Acetyl-L-carnitine hydrochloride (99%) and α-lipoic acid (98%) are available from Sigma-Aldrich (Sigma-Aldrich, 2003b).

α-Lipoic acid is a racemic mixture of R+ (d-form) and S- (l-form) enantiomers. The R-isomer [CAS No. 1200-22-2] is the natural co-factor of pyruvate dehydrogenase and α-ketoglutarate dehydrogenase in mitochondria (Hermann *et al.*, 1996). The R-form of α-lipoic acid can be purified from the S-form but deteriorates rapidly at room temperature (Juvenon, Inc., 2003a).

Another racemic mixture, dl-α-lipoic acid [CAS No. 1077-28-7] is also available from Sigma-Aldrich at 99% purity (Sigma-Aldrich, 2003b).
EXPOSURE INFORMATION

Production and Producers:

Manufacturing Process: Acetyl-L-carnitine hydrochloride is prepared by acetylation of L-carnitine (Dubroeucq et al., 2003).

α-Lipoic acid can be prepared by reacting 6,8-dichlorooctanoic acid with sodium disulfide. Industrial production of α-lipoic acid involves the conversion of monomethyl or monoethyl adipate into the corresponding acid chloride by reaction with thionyl chloride. This mixture is treated with ethylene and anhydrous aluminum chloride yielding an intermediate compound that after reduction is treated with sodium disulfide. This process produces a dithionooctyl ester that gives α-lipoic acid after hydrolysis (Csomós & Leuschner, 2003).

Producers and Importers: Chemical Sources International (2003) lists the following US suppliers: 6 for acetyl-L-carnitine hydrochloride, 9 for α-lipoic acid, 5 for α-lipoic acid (as thioctic acid), and 11 for dl-α-lipoic acid.

Acetyl-L-carnitine hydrochloride is manufactured and/or distributed by Aceto Corp.; Barrington Chemical Corp.; Compound Solutions, Inc.; Fabrichem, Inc.; Marcor Development Corp.; Robima Corp.; Sigma-Tau Health Science Inc.; Tanabe U.S.A., Inc.; and Westco Fine Ingredients, Inc. (Chemical Week Associates 2003; Tilton, 2002).

Acetyl-L-Carnitine/\(\alpha\)-Lipoic Acid
5080-50-2 / 62-46-4


dl-\(\alpha\)-Lipoic acid is manufactured and/or distributed by Acros Organics USA; Aceto Corp.; AIDP Inc.; Degussa Corporation; F.T.L. International, Inc.; Marcor Development Corp.; Santec Chemicals Corp.; and Schweizerhall, Inc. (Carroll, 2002; Hunter, 2002; Tilton, 2002).

Production/Import/Export Level: Acetyl-L-carnitine hydrochloride and \(\alpha\)-lipoic acid are not listed in the EPA Toxic Substances Control Act (TSCA) Inventory (ChemID, 2003).

In the 36-month period from March 2000 to March 2003, the Port Import/Export Reporting Service (PIERS) database reported \(\alpha\)-lipoic acid imports with a cargo weight of 376,903 pounds. The exporting countries were China and South Korea (Dialog Information Service, 2003).

Use Pattern: Juvenon, Inc., founded by Dr. Bruce Ames, is the primary developer of dietary supplements based on a combination of acetyl-L-carnitine and \(\alpha\)-lipoic acid. Juvenon markets this dietary supplement, Juvenon Energy Formula™ as an anti-aging product to increase natural energy and reduce toxic oxidants and cellular damage. Thus, the market segment for Juvenon Energy Formula™ is comprised of individuals over 50 years of age (Juvenon, Inc., 2003a,b).

Other dietary supplement suppliers produce acetyl-L-carnitine/ \(\alpha\)-lipoic acid formulations that include additional ingredients, such as coenzyme Q10, vitamin C, vitamin E, creatine,
or Gingko Biloba extract. Supplemental acetyl-L-carnitine is advertised on the Internet as a substance that can enhance cognition, improve memory, and provide more energy by increasing metabolic activity (Biosynergy, 2003; Center of Hope, 2003; iHerb.com, 2003).

Juvenon, Inc., has posted information on the company website relating to research it is conducting on acetyl-L-carnitine/α-lipoic acid supplements in humans, and has posted information on its website. In a single-center, randomized, double-blind, placebo-controlled study lasting 17 weeks, Juvenon Energy Formula™ (acetyl-L-carnitine/α-lipoic acid) given to 18 healthy men, age 60-71, produced positive effects for 8 of 9 measures of exercise-induced oxidative stress in the majority of subjects. Based on scores from the Psychological General Well Being Index, the majority of subjects had higher scores assessing perceptions related to mood and general health (Juvenon, Inc., 2003c).

Juvenon, Inc. is presently conducting a clinical trial to evaluate the effect of Juvenon Energy Formula™ on cardiovascular patients. The goal is to measure effects on endothelial function and blood pressure in 40 elderly subjects (55-95 years of age) (Juvenon, Inc., 2003d).

Acetyl-L-carnitine hydrochloride has demonstrated some efficacy as a neuroprotective agent and its administration may be indicated for use in strokes, Alzheimer’s disease, Down’s syndrome, and managing some neuropathies (Hendler & Rorvik, 2001; Salvioli & Neri, 1994). Other human conditions reported to benefit from acetyl-L-carnitine administration are geriatric depression, cerebellar ataxia, type 2 diabetes, and HIV (Zdanowicz, 2001).

Acetyl-L-carnitine alone is also marketed as an anti-aging dietary supplement (Life Extension Magazine, 2000). It is thought that acetyl-L-carnitine may improve mental impairments in aging humans and animals through mechanisms that increase energy metabolism in the brain and enhance brain cholinergic activity through acetylcholine release.
(Bossoni & Carpi, 1986; Imperato et al., 1989; Toth et al., 1993). Animal studies suggest that supplemental acetyl-L-carnitine may enhance cognitive functioning by elevating nerve growth factor (NGF) levels in the brain, stabilizing cell membranes and improving synaptic morphology, and decreasing the accumulation of potentially toxic fatty acids (Zdanowicz, 2001).

α-Lipoic acid dietary supplements are also sold as antioxidants and free radical quenchers. Supplemental α-lipoic acid is currently used in Germany to treat peripheral nerve degeneration resulting from diabetes. It has also been used as a therapeutic agent for hepatic coma, chronic hepatitis, cirrhosis of the liver, and has been partially successful in treating glaucoma and Amanita mushroom poisoning (Biosynergy, 2003; Conemaugh Health System, 2001a; Csomós & Leuschner, 2003; Herbal Advisor, 2003; Nichols, 1977).

The beneficial effects of α-lipoic acid have been attributed to its anti-oxidant activity. α-Lipoic acid can scavenge hydroxyl radicals, hypochlorous acid, and singlet oxygen, but not hydrogen peroxide or peroxyl and superoxide radicals (Nichols, 1977; Scott et al., 1994).

The National Center for Complementary and Alternative Medicine (NCCAM) is conducting two clinical trials involving α-lipoic acid. A Phase II clinical trial to determine immunomodulatory and antiviral effects of α-lipoic acid in HIV-infected persons unresponsive to highly active antiretroviral treatment is recruiting 42 patients and anticipates a 2003 completion date. A Phase I/Phase II project to assess three natural anti-oxidant regimens, including α-lipoic acid/essential fatty acids, for their ability to suppress autoimmune encephalomyelitis in multiple sclerosis patients was not yet open for patient recruitment as of the last record review date (ClinicalTrials.gov, 2003).

As of March 2003, the number of patents on file with the US Patent and Trademark Office for acetyl-L-carnitine and α-lipoic acid were 140 and 1,059, respectively (US Patent and Trademark Office, 2003).
Human Exposure:

**Consumer Exposure:** One source of human exposure to acetyl-L-carnitine and α-lipoic acid occurs from their ingestion in dietary supplements. These dietary supplements appeal to older persons as substances that rejuvenate the body by increasing available energy and mental acuity, although students and athletes are a secondary target market (Conemaugh Health System, 2001a,b).

The natural dietary source of acetyl-L-carnitine is red meat while α-lipoic acid is present in meats and vegetables such as spinach (Juvenon, Inc., 2003a).

There are no standard doses for acetyl-L-carnitine and α-lipoic acid supplements. The highest doses recommended for acetyl-L-carnitine (no salt specified) and for α-lipoic acid are 1,500 and 600 mg/day, respectively (Bio synergy, 2003; Conemaugh Health System, 2001a; Juvenon, Inc., 2003a).

Other supplements have lower quantities of these compounds, 20-30 mg of acetyl-L-carnitine (no salt specified) and 20-50 mg of α-lipoic acid, but additional antioxidants may be present in these formulations (Bio synergy, 2003; Center of Hope, 2003; iHerb.com, 2003).

An oral dose of 800 mg per day of α-lipoic acid was reported to be beneficial in treating patients with diabetic neuropathies (Conemaugh Health System, 2001a).

**Occupational Exposure:** The National Occupational Exposure Survey (NOES), which was conducted by the National Institute for Occupational Safety and Health (NIOSH) between 1981-1983, estimated that 429 workers, including 141 females, in 138 facilities representing 2 industries were potentially exposed to α-lipoic acid in the workplace (RTECS, 1996). The NOES database does not contain information on the frequency, level, or duration of
exposure to workers of any chemical listed therein, and it does not reflect recent increased usage of α-lipoic acid as a dietary supplement and therapeutic agent.

**Environmental Occurrence:** As described in the section on metabolism, acetyl-L-carnitine and α-lipoic acid are produced in vertebrates naturally. In addition, α-lipoic acid has been described as a growth factor for certain protozoa and bacteria (Csomós & Leuschner, 2003). No information on any other environmental occurrence of acetyl-L-carnitine or α-lipoic acid was identified in the available literature.

**Regulatory Status:** No standards or guidelines have been set by NIOSH or the Occupational Safety and Health Administration (OSHA) for occupational exposure to or workplace allowable levels of acetyl-L-carnitine hydrochloride or α-lipoic acid. Furthermore, these compounds were not on the American Conference of Governmental Industrial Hygienists (ACGIH) list of compounds for which recommendations for a threshold limit value (TLV) or biological exposure index (BEI) are made.

Since 1994, dietary supplements have been regulated under the Dietary Supplement Health and Education Act (DSHEA). The DSHEA requires no proof of safety for dietary supplements on the market prior to October 15, 1994. Labeling requirements for dietary supplements allow warnings and dosage recommendation as well as substantiated “structure or function” claims. All claims must prominently note that they have not been evaluated by the FDA, and they must bear the statement “This product is not intended to diagnose, treat, cure, or prevent any disease” (FDA, 1995).
TOXICOLOGY INFORMATION

Human Data: No epidemiological studies or case reports investigating exposure to acetyl-L-carnitine and/or α-lipoic acid and cancer risk in humans were identified in the available literature.

Juvenon, Inc. performed a study in humans given Juvenon Energy Formula™ (500 mg of acetyl-L-carnitine and 200 mg of α-lipoic acid) twice a day. No toxic endpoints were reported or investigated in this study. Another clinical trial with Juvenon Energy Formula™ to assess potential benefits on endothelial function is underway (Juvenon, Inc., 2003c,d).

Mild adverse reactions, including gastrointestinal effects, have been reported after acetyl-L-carnitine administration. However, acetyl-L-carnitine may interfere with thyroid metabolism. In individuals with seizure disorders, an increase in seizure frequency and severity has also been reported (De Grandis et al., 1995; Hendler & Rorvik, 2001; Juvenon, Inc., 2003a; Zdanowicz, 2001).

In studies where acetyl-L-carnitine was given to Alzheimer’s disease patients at doses of 1.5-3.0 g/day for two to six months, no serious side effects were observed. In a clinical trial where 1,097 patients received 1,000 mg/day of acetyl-L-carnitine hydrochloride intramuscularly (i.m.) route for 10 days followed by 2,000 mg orally for 20 days, six patients withdrew from the study due to gastrointestinal side effects (Zdanowicz, 2001).

Oral α-lipoic acid has been well tolerated in doses up to 600 mg/day. Adverse side effects reported were allergic skin conditions, possible hypoglycemia in diabetic patients, and thiamine deficiency at high doses (Juvenon, Inc., 2003a; Nichols, 1997).

The National Center for Complementary and Alternative Medicine (NCCAM) is conducting a Phase 2 clinical trial to investigate the immunomodulatory and antiretroviral effects of
dietary α-lipoic acid in HIV-infected patients. NCCAM is also sponsoring studies of antioxidant therapies including a combination of α-lipoic acid and essential fatty acids in animal models of multiple sclerosis (MS). Clinical trials on successful therapies will be conducted in MS patients (ClinicalTrials.gov, 2003a,b).

**Animal Data:** No 2-year carcinogenicity studies of acetyl-L-carnitine hydrochloride and/or α-lipoic acid compounds in animals were identified in the available literature.

**Acute Toxicity:**

The LD$_{50}$ values for α-lipoic acid are listed in Table 1.

<table>
<thead>
<tr>
<th>Species</th>
<th>Route of administration</th>
<th>LD$_{50}$ (mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>mouse</td>
<td>oral</td>
<td>502</td>
</tr>
<tr>
<td>rat</td>
<td>oral</td>
<td>1,130</td>
</tr>
<tr>
<td>dog</td>
<td>oral</td>
<td>400-500</td>
</tr>
</tbody>
</table>

Source: Nichols, 1997; RTECS, 1996

α-Lipoic acid, administered intraperitoneally (i.p.) to rats at 0.5-1.5 mmol/kg, inhibited glycine conjugation of injected benzoic acid and depleted hepatic acetyl coenzyme A (CoA), L-carnitine, and glutathione, but not ATP, while increasing hepatic levels of glycine. It also reduced urine formation in a dose-dependent manner causing acute renal failure at the highest dose (Gregus et al., 1996).

α-Lipoic acid administered intravenously (i.v.) at 60 or 100 mg/kg inhibited gluconeogenesis, causing a rapid reduction of blood glucose in both diabetic and control rats. This effect was secondary to α-lipoic acid interference in fatty acid oxidation in the liver (Khamaisi et al., 1999).
**Subchronic Toxicity:** No information on the subchronic toxicity of acetyl-L-carnitine, α-lipoic acid, or combinations was found in the available literature.

**Short-Term Tests:** In a study completed in 1998, α-lipoic acid was negative in *Salmonella typhimurium* TA97, TA98, TA100, and TA1535 with and without rat and hamster liver S-9 (NTP, 2004).

**Metabolism:**

*Acetyl-L-Carnitine:* Acetyl-L-carnitine is formed in the mitochondria by carnitine acetyltransferase, which combines L-carnitine with an acetyl group from CoA. Acetyl-L-carnitine is then transported across the inner mitochondrial membrane by carnitine acetyltranslocase, where it diffuses out of the mitochondria into the cytoplasm and serves as a source of acetyl groups for cytosolic proteins. The acetyl group also provides for the generation of acetylcholine (Hendler & Rorvik, 2001; Zdanowicz, 2001).

Acetyl-L-carnitine does not significantly bind to albumin or other serum proteins. It readily crosses the blood-brain barrier and its elimination occurs via the kidneys (Zdanowicz, 2001).

*α-Lipoic Acid:* In the mitochondria, α-lipoic acid is covalently linked to a lysyl residue as a lipoamide in proteins. At the expense of NADPH, α-lipoic acid is reduced to dihydrolipoic acid (DHLA) which reacts with oxidants such as superoxide and hydroxy radicals. It also reduces oxidized vitamin C and glutathione, which in turn recycle ascorbic acid and vitamin E (Figure 1). α-Lipoic acid also acts as a coenzyme in mitochondrial multienzyme complexes in the oxidative decarboxylation of α-keto acids such as pyruvate and α-ketoglutarate (Breithaupt-Grögler et al., 1999; Csomós & Leuschner, 2003; Liu et al., 2002a).
Food-derived α-lipoic acid originates from multienzyme complexes. Due to the lack of effective proteolytic enzymes, α-lipoic acid from the diet is absorbed as a lipooyllysine. In addition, α-lipoic acid can be produced by de novo biosynthesis, where cysteine appears to be the source of sulfur and octanoate serves as the intermediate precursor for the 8-carbon fatty acid. Only minor amounts of α-lipoic acid will enter the circulation from food or biosynthesis. The concentration of α-lipoic acid has been found to be highest in the liver (Biewenga et al., 1997; Csomós & Leuschner, 2003; Nichols, 1997).

In humans, α-lipoic acid is excreted mainly in the urine within 24 hr of a single oral or parenteral dose. The main plasma and urine metabolite of α-lipoic acid is 4,6-bismethylmercapto-hexanoic acid following oral administration, indicating that α-lipoic acid undergoes predominantly β-oxidation and methylation at the sulfur atoms. In addition, methyl sulfoxide metabolites are also formed (Hermann et al., 1996; Nichols, 1997; Schupke et al., 2001; Teichert et al., 1998).

In humans administered a single oral dose of α-lipoic acid, maximum plasma concentrations of both enantiomers were attained rapidly (≤1 hr) and were 40-50 percent higher for the $R$-form. The plasma half-lives were short (<1 hr) for both enantiomers, however the $S$-form has a higher total plasma clearance, suggesting stereoselective
differences during drug absorption, transport, and hepatic extraction (Breithaupt-Grögler et al., 1999; Hermann et al., 1996).

α-Lipoic acid enantiomers were absorbed more slowly from solid oral formulations than from oral solutions. Food intake also significantly reduced the bioavailability of α-lipoic acid in healthy volunteers (Hermann et al., 1996; Teichert et al., 1998).

In animal studies, 93 percent of a dose of radioactive-labeled α-lipoic acid was absorbed at all parts of the gastrointestinal tract. Another report found that 25 percent of the administered dose of radiolabeled α-lipoic acid was exhaled as CO₂ within two hours, reaching 30 percent within 24 hours of administration (Harrison & McCormick, 1974; Peter & Borbe, 1995).

Uptake of exogenously administered α-lipoic acid occurs in all areas of the central nervous system and peripheral nerves (Packer et al., 1997).

Other Biological Effects:

Tumor Inhibition Studies: α-Lipoic acid, given in drinking water at 45 and 180 mg/kg/day to male Sprague-Dawley rats administered 10 mg/kg of N-nitroso-diethylamine orally twice weekly for life, did not significantly change tumor frequencies, induction times, or histology of liver and esophageal tumors (Habs et al., 1980).

Intravenous (i.v.), subcutaneous (s.c.), or intraperitoneal (i.p.) administration of α-lipoic acid at a daily dose of 100 mg/kg for five days to NMRI mice implanted with Ehrlich ascites carcinoma had no effects on tumor growth. A decrease in survival time was thought to be due to the high dose of α-lipoic acid administered (Kunstler, 1980).

Reproductive or Developmental Effects Studies: α-Lipoic acid administered i.p. to pregnant diabetic rats reduced the number of malformations and fetal loss when compared to the
offspring of untreated diabetic rats. \(\alpha\)-Lipoic acid also protected against growth reduction of diabetic embryos (Wiznitzer et al., 1996).

\(\alpha\)-Lipoic acid induced malformations of body segments and appendages in developing horseshoe crabs (Itow, 1980).

**Studies Designed to Investigate Beneficial Effects of Acetyl-L-Carnitine or \(\alpha\)-Lipoic Acid**

- **Effects on Mitochondrial Metabolic Activity:**
  
  Carnitine acetyltransferase (CAT) regenerates CoA in the mitochondria allowing \(\beta\)-oxidation to proceed. A decrease in CAT activity in brain and muscles has been shown to be age-related. The combination of acetyl-L-carnitine hydrochloride and \(R-\alpha\)-lipoic acid given orally to old rats significantly restored CAT activity and CAT’s binding affinity for the substrates acetyl-L-carnitine and CoA to the levels observed in young rats (Liu et al., 2002b).

  Oral administration of acetyl-L-carnitine hydrochloride to rats reversed the age-associated decrease in cytochrome \(c\) oxidase and phosphate carrier activity in heart mitochondria (Hagen et al., 2002a).

- **Pro- and Anti-oxidant Properties:**

  Acetyl-L-carnitine hydrochloride and \(R-\alpha\)-lipoic acid dietary administration increased hepatocellular ascorbate in old rats to levels comparable to those found in young untreated rats (Hagen et al., 2002b).

  Malondialdehyde (MDA) levels in brain and hepatocytes are significantly higher in old rats when compared to young rats. Dietary administration of acetyl-L-carnitine hydrochloride/\(R-\alpha\)-lipoic acid combinations or \(R-\alpha\)-lipoic acid alone lowered the brain MDA concentrations in old rats. Oral doses of acetyl-L-carnitine hydrochloride and \(\alpha\)-lipoic acid also decreased hepatic MDA levels in old rats (Hagen et al., 2002b; Liu et al., 2002b).

  Oral doses of acetyl-L-carnitine increased the rate of oxidant production in the liver of old rats when compared to cells from control old animals. This regimen did not raise the oxidative stress in cardiac cells of old rats (Hagen et al., 2002a).

  \(\alpha\)-Lipoic acid increased *in vivo* and *in vitro* intracellular glutathione concentrations (Busse et al., 1992; Packer, 1998).
Preincubation of non-diabetic and diabetic human erythrocytes with oxidized α-lipoic acid increased nitrite-mediated formation of methemoglobin but significantly reduced the 4-aminophenol-mediated formation of methemoglobin in diabetic and non-diabetic cells (Coleman & Walker, 2000).

**Effects on Neuronal Function:**

Dietary administration of acetyl-L-carnitine hydrochloride and/or R-α-lipoic acid improved age-related mitochondrial structural decay in hippocampal neurons in old rats (Liu et al., 2002a).

Acetyl-L-carnitine accelerated the maturation of cerebellar neurons in vitro, activated nerve growth factor receptors, and prevented the loss of substance P in the peripheral nerves in diabetic animals (De Grandis et al., 1995).

Old rats given oral α-lipoic acid showed delayed hearing loss while rats treated with acetyl-L-carnitine hydrochloride experienced hearing improvement (Seidman et al., 2000).

**Regulation of Programmed Cell Death:**

Acetyl-L-carnitine administration to HIV-1-infected subjects decreased the levels of apoptotic CD4 T-cells (Di Marzio et al., 1999).

*In vitro* Fas-mediated apoptosis of human acute leukemic Jurkat T-cells was significantly potentiated by α-lipoic acid through an increase in caspase 3 activity (Sen et al., 1999).

**Effects on Gene Expression:**

α-Lipoic acid inhibited the activation of the NF-κB transcription factor induced by tumor necrosis factor-α in Jurkat T cells (Packer, 1998).

**Structure-Activity Relationships:** Three compounds structurally-related to acetyl-L-carnitine and two compounds structurally-related to α-lipoic acid have been selected for review. These chemicals were L-carnitine, benzoylcarnitine, propionylcarnitine, lipoamide, and dihydrolipoic acid. No information on the carcinogenicity of any of these chemicals was identified in the available literature.

A brief review of the pharmacological and toxicological data on the five chemicals is presented in Table 2.
Table 2. Pharmacological and Toxicological Information on Chemicals Structurally-Related to Acetyl-L-Carnitine and α-Lipoic Acid

<table>
<thead>
<tr>
<th>Chemical/CAS No.</th>
<th>Structure</th>
<th>Pharmacological/Toxicological Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>L-Carnitine 541-15-1</td>
<td><img src="image" alt="Structure" /></td>
<td>Not mutagenic in standard assays (Hendler &amp; Rorvik, 2001)</td>
</tr>
<tr>
<td>Benzoylcarnitine 105450-08-6</td>
<td><img src="image" alt="Structure" /></td>
<td>Urinary metabolite of sodium benzoate and L-carnitine therapy to treat hyperammonemia (Sakuma et al., 1989)</td>
</tr>
<tr>
<td>Propionylcarnitine 17298-37-2</td>
<td><img src="image" alt="Structure" /></td>
<td>Anti-oxidant activity (Hendler and Rorvik, 2001; Vanella et al., 2000)</td>
</tr>
<tr>
<td>Lipoamide 940-69-2</td>
<td><img src="image" alt="Structure" /></td>
<td>Anti-oxidant activity (Bustamante et al., 1995; Goloshchapov &amp; Agranovskii, 1976)</td>
</tr>
<tr>
<td>Dihydrolipoic acid 462-20-4</td>
<td><img src="image" alt="Structure" /></td>
<td>Anti-oxidant activity (Biewenga et al., 1997; Bustamante et al., 1995)</td>
</tr>
</tbody>
</table>
References


